U.S. flag An official website of the United States government
  1. Home
  2. Advisory Committees
  3. Advisory Committee Calendar
  4. Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Announcement - 02/28/2023
  1. Advisory Committee Calendar

Advisory Committee Meeting | Virtual

Event Title
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Announcement
February 28, 2023 - March 1, 2023

Scheduled

Date:
February 28, 2023 - March 1, 2023
Day1:
- ET
Day2:
- ET

What is an advisory committee?

Advisory committees provide independent expert advice to the FDA on broad scientific topics or on certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Please see, "Advisory Committees Give FDA Critical Advice and the Public a Voice," for more information.

Please note that due to the impact of the COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform.

How to Attend: 



Agenda
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On February 28, 2023, under Topic 1, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in Biologics License Application (BLA) 125769 (STN 125769/0), for active immunization for the prevention of acute respiratory disease and lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older. On March 1, 2023, under Topic 2, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of AREXVY (Respiratory Syncytial Virus Vaccine, Recombinant, Adjuvanted), manufactured by GSK, with a requested indication, in BLA 125775 (STN 125775/0), for active immunization for the prevention of LRTD caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older.


Meeting Materials
FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, any background material will be made publicly available at the time of the advisory committee meeting, and additional materials will be posted on FDA's website after the meeting.  

Materials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page.

The meeting will include slide presentations with audio components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.


Public Participation Information
Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. 

The Docket Number is FDA-2023-N-0246

FDA is establishing a docket for public comment on this meeting. The docket number is FDA-2023-N-0246. The docket will close on February 27, 2023. Either electronic or written comments on this public meeting must be submitted by February 27, 2023. Please note that late, untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of February 27, 2023. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Comments received on or before February 20, 2023, will be provided to the committee. Comments received after February 20, 2023, and by February 27, 2023, will be taken into consideration by FDA. In the event that the meeting is canceled, FDA will continue to evaluate any relevant applications or information, and consider any comments submitted to the docket, as appropriate.

You may submit comments as follows: 

Electronic Submissions

  • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
  • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

  • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
  • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA-2023-N-0246 for “Vaccines and Related Biological Products Advisory Committee (VRBPAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments.” Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

  • Confidential Submissions-- To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” FDA will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify the information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.


FOR FURTHER INFORMATION CONTACT: Sussan Paydar or Prabhakara Atreya, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD 20993-0002, 240-506-4946, CBERVRBPAC@fda.hhs.gov; or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the FDA’s website at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.


ORAL PRESENTATIONS: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. All electronic and written submissions submitted to the Dockets (see ADDRESSES) on or before February 20, 2023, will be provided to the committee. Comments received after February 20, 2023, and by February 27, 2023, will be taken into consideration by FDA. Oral presentations from the public will be scheduled approximately between 1:10 p.m. and 2:10 p.m. Eastern Time on February 28, 2023, and approximately between 12:30 and 1:30 p.m. Eastern Time on March 1, 2023. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, along with their names, email addresses, and direct contact phone numbers of proposed participants, on or before 12 p.m. Eastern Time on February 15, 2023. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by 6 p.m. Eastern Time on February 22, 2023.


Webcast Information
CBER plans to provide a free of charge a live webcast of the Vaccines and Related Biological Products Advisory Committee meeting. 

If there are instances where the webcast transmission is not successful, staff will work to re-establish the transmission as soon as possible.


Contact Information

  • Sussan Paydar or Prabhakara Atreya: CBERVRBPAC@fda.hhs.gov
  • FDA Advisory Committee Information Line:
    1-800-741-8138 (301-443-0572 in the Washington, DC area) Please call the Information Line for up-to-date information on this meeting.
  • For press inquiries, please contact the Office of Media Affairs at fdaoma@fda.hhs.gov or 301-796-4540.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Official FR Notice


A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s website or call the committee’s Designated Federal Officer (see Contact Information) to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact the committee’s Designated Federal Officer (see Contact Information) at least 7 days in advance of the meeting.

Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).


Event Materials

Title File Type/Size Source Organization
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Waivers for Conflicts of Interest pdf (84.19 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Voting Questions- Pfizer pdf (106.77 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Voting Questions- GSK pdf (110.61 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Draft Roster pdf (293.17 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Draft Agenda pdf (270.14 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Briefing Document- Sponsor: Pfizer pdf (1.23 MB) Non-FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Briefing Document- Sponsor: GSK- Errata pdf (199.89 KB) Non-FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Briefing Document- FDA: Applicant- Pfizer pdf (653.89 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Briefing Document- FDA: Applicant- GSK pdf (674.49 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Briefing Document- Sponsor: GSK pdf (2.14 MB) Non-FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Presentation- RSVPreF3 Vaccine for Respiratory Syncytial Virus (RSV) in Older Adults pdf (2.18 MB) Non-FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Presentation- FDA Introduction ABRYSVO BLA pdf (616.20 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Presentation- FDA Introduction AREXVY BLA pdf (628.39 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Presentation- FDA Review of Efficacy and Safety of ABRYSVO BLA pdf (1.14 MB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Presentation- FDA Review of Efficacy and Safety of AREXVY BLA pdf (764.57 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Presentation- RSV Epidemiology and Disease Burden in Older Adults pdf (2.25 MB) Non-FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Presentation- RSV Immunity, Durability, and Reinfection pdf (1.27 MB) Non-FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Presentation- RSV virology, strain variation, and surveillance measures pdf (1.92 MB) Non-FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Presentation- Bivalent RSV Prefusion F Vaccine in Adults Over 60 Years of Age pdf (1.61 MB) Non-FDA
Vaccines and Related Biological Products Advisory Committee February 28-March 1, 2023 Meeting Final Roster pdf (273.43 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28, 2023 Meeting Transcript pdf (1.55 MB) FDA
Vaccines and Related Biological Products Advisory Committee March 1, 2023 Meeting Transcript pdf (1.19 MB) FDA
Vaccines and Related Biological Products Advisory Committee March 1, 2023 Meeting Summary Minutes pdf (265.41 KB) FDA
Vaccines and Related Biological Products Advisory Committee February 28, 2023 Meeting Summary Minutes pdf (218.42 KB) FDA

 
Back to Top